Received February 18, 2007; revised and accepted March 17, 2008.
From the 1Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia; 2Department of Obstetrics and Gynaecology, University of Sydney, NSW, Australia; 3Office for Gender and Health, Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia.
Funding/support: The content of this article was presented by Dr. Burger during the NAMS/Wyeth Wulf H. Utian Endowed Lecture on October 5, 2007, in Dallas, TX. A generous endowment to NAMS from Wyeth Pharmaceuticals established this lectureship, with faculty selected by the NAMS Scientific Program Committee.
Financial disclosure: Dr. Burger is a dinner speaker, advisory board member, or consultant for Wyeth Pharmaceuticals, Organon (Australia Pty Ltd), and Novo Nordisk. Dr. Dennerstein is a consultant or advisory board member for Boehringer-Ingelheim, Bayer Schering Pharma Women's Healthcare, Wyeth Pharmaceuticals, Pfizer, and Besins. Drs. Hale and Robertson report no disclosures.
Address correspondence to: Henry G. Burger, MD, FRACP, Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, Victoria 3168, Australia. E-mail: [email protected]